General
Preferred name
PX-12
Synonyms
IV-2 ()
PX12 ()
PX 12 ()
Disulfide compound 1 ()
PMID26882240-Compound-2 ()
DB05448, 1-methyl propyl 2-imidazolyl disulfide ()
P&D ID
PD003683
CAS
141400-58-0
Tags
available
drug candidate
Drug indication
Coronavirus Disease 2019 (COVID-19)
pancreatic neoplasm
Cancer
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
PX-12 is a small molecule irreversible inhibitor of the redox protein thioredoxin. Thioredoxin is involved in the first unique step in DNA synthesis. Thioredoxin also provides control over a number of transcription factors affecting cell proliferation and death through the mechanism of redox regulation; Trx regulates cell growth through the following steps:; 1) Trx is reduced into its active state, Trx (red) by the enzyme thioredoxin reductase.; 2) Trx enters the nucleus to regulate transcription factor activity (factors which affect DNA replication).; 3) Trx is excreted out of cell where it works with other growth factors (GF) to stimulate cell growth.; ; It has been shown that many cancer cells secrete thioredoxin; increased levels of thioredoxin protein have been reported in a wide range of human cancers including hepatoma, lung, squamous cervical carcinoma, primary gastric cancers, and colorectal carcinomas;thioredoxin stimulates the growth of a wide variety of human leukemia and solid tumor cell lines; thioredoxin, when it is over-produced, transforms normal cells into cancer cells; thioredoxin is a potent inhibitor of apoptosis and provides a survival as well as a growth advantage to tumors; elevated tumor thioredoxin levels have been associated with decreased patient survival in colon cancer and NSCLC; and elevated thioredoxin levels cause a decrease in sensitivity of cells to cancer drugs such as doxorubicin (14 fold), vincristine (8 fold), cisplatin (5 fold), and cytosine arabinoside (13 fold). Therefore PX-12, by limiting the over-expression of thioredoxin in human tumors, could reduce resistance to chemotherapy.;
DESCRIPTION
PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1 (Trx-1); inhibits the growth of MCF-7 and HT-29 cells with IC50 values of 1.9 and 2.9 ¦ÌM, respectively.
PRICE
39
DESCRIPTION
PX-12 (PX12) (1-methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1?? and vascular endothelial growth factor (VEGF) and inhibits tumor growth in animal models. Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced metastatic cancer. Initial trials correlated doses of Px-12 with increased patient survival.
DESCRIPTION
inhibitor of thioredoxin-1
(Informer Set)
DESCRIPTION
PX-12 is an irreversible inhibitor of Trx-1 currently in clinical development as an antitumor agent. The research results suggest that the lowering of elevated levels of plasma Trx-1 in cancer patients may provide a surrogate for the inhibition of tumor Trx-1 by PX-12.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
PX-12 (PX12) (1-methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1α and vascular endothelial growth factor (VEGF) and inhibits tumor growth in animal models. Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced metastatic cancer. Initial trials correlated doses of Px-12 with increased patient survival.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Selective IGF1R inhibitor
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
5
Organisms
1
Compound Sets
15
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
DrugBank
Informer Set
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
24
Molecular Weight
188.04
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
1
cLogP
2.95
TPSA
28.68
Fraction CSP3
0.57
Chiral centers
1.0
Largest ring
5.0
QED
0.74
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
TXN
TRX (HT-29 cells)
TRX (MCF-7)
Apoptosis
COVID-19,Thioredoxin
Compound status
clinical
Primary Target
Thioredoxin Reductases
MOA
Inhibitor
Thioredoxin 1 competitive irrreversible inhibitor
Member status
member
Therapeutic Class
Anticancer Agents
Antiviral Agents
Pathway
Metabolism
Source data
